<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00366678</url>
  </required_header>
  <id_info>
    <org_study_id>6096A1-008</org_study_id>
    <nct_id>NCT00366678</nct_id>
  </id_info>
  <brief_title>Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants</brief_title>
  <official_title>A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in France.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and immunogenicity of a
      13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given
      concomitantly with routine pediatric vaccines in France.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria, Tetanus, Hemophilus Influenza Type b (Hib), Poliomyelitis (Type 1, 2, 3), Pertussis Toxin (PT) and Filamentous Hemagglutinin (FHA) in 13vPnC Group Relative to 7vPnC Group</measure>
    <time_frame>One Month After the 3-Dose Infant Series (at 5 months of age) and the Toddler Dose (at 13 months of age)</time_frame>
    <description>Percentage of participants achieving predefined antibody threshold levels ≥0.1 IU/mL for diphtheria, ≥0.1 IU/mL for tetanus, ≥ 0.15 μg/mL for Hib polyribosylribitol phosphate (PRP), antibody titer ≥1:8 for polio and ≥5 EU/mL for pertussis (PT and FHA) with the corresponding 95% CI for each concomitant antigen are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration (GMC) as Measured by Enzyme-linked Immunosorbent Assay (ELISA) for Diphtheria Toxoid and Tetanus Toxoid in 13vPnC Group Relative to 7vPnC Group</measure>
    <time_frame>One month after the 3-Dose Infant Series (at 5 months of age) and the Toddler Dose (at 13 months of age)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration (GMC) for Haemophilus Influenzae Type b (Hib) in 13vPnC Group Relative to 7vPnC Group</measure>
    <time_frame>One month after the 3-Dose Infant Series (at 5 months of age) and the Toddler Dose (at 13 months of age)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration (GMC) as Measured by Enzyme-linked Immunosorbent Assay (ELISA) for Poliomyelitis (Type 1, Type 2 and Type 3) in 13vPnC Group Relative to 7vPnC Group</measure>
    <time_frame>One month after the 3-Dose Infant Series (at 5 months of age) and the Toddler Dose (at 13 months of age)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration (GMC) as Measured by ELISA for Pertussis Toxin (PT) and Pertussis Filamentous Hemagglutinin (FHA) in 13vPnC Group Relative to 7vPnC Group</measure>
    <time_frame>One month after the 3-Dose Infant Series (at 5 months of age) and the Toddler Dose (at 13 months of age)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving a Pneumococcal Antibody Level ≥0.35µg/mL (ELISA) After the 3-Dose Infant Series of 13vPnC</measure>
    <time_frame>One month after the 3-Dose Infant Series (at 5 months of age)</time_frame>
    <description>Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Pre-Specified Local Reactions</measure>
    <time_frame>During the 4-day period after each dose</time_frame>
    <description>Local reactions were collected using an electronic diary. Tenderness (Tender)was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (Sev) (&gt;7.0 cm). Participants may be represented in more than 1 category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Pre-Specified Systemic Events</measure>
    <time_frame>During the 4-day period after each dose</time_frame>
    <description>Systemic events (fever [fv] ≥ 37.5 degrees Celsius [C], fever ≥ 38 C but ≤ 39 C, fever &gt;39 C but ≤ 40 C, fever &gt; 40 C, decreased [decr] appetite, irritability, increased [incr] sleep, decreased sleep, hives, use of medication [med] to treat symptoms [sx], and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the 3-Dose Infant Series of 13vPnC</measure>
    <time_frame>One month after the 3-Dose Infant Series (at 5 months of age)</time_frame>
    <description>Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Pneumococcal Antibody Level ≥0.35µg/mL (ELISA) After the Toddler Dose in the 13vPnC/13vPnC, 7vPnC/7vPnC and 7vPnC/13vPnC Groups</measure>
    <time_frame>One month after the toddler dose (at 13 months of age)</time_frame>
    <description>Percentages of participants achieving World health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumococcal Geometric Mean Concentration (GMC) Before and After the Toddler Dose in the 13vPnC/13vPnC, 7vPnC/7vPnC and 7vPnC/13vPnC Groups</measure>
    <time_frame>One month after the Toddler Dose (at 13 months of age)</time_frame>
    <description>Antibody GMC as measured by ELISA for 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Antibody Titer ≥1:8 After the Toddler Dose in 13vPnC/13vPnC and 7vPnC/13vPnC Groups</measure>
    <time_frame>One month after the toddler dose (at 13 months of age)</time_frame>
    <description>Percentage of participants achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) in 13vPnC/13vPnC and 7vPnC/13vPnC Groups After the Toddler Dose</measure>
    <time_frame>One month after the toddler dose (at 13 months of age)</time_frame>
    <description>GMT as measured by opsonophagocytic activity assay (OPA) for 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">613</enrollment>
  <condition>Vaccines, Pneumococcal</condition>
  <arm_group>
    <arm_group_label>13-valent pneumococcal conjugate vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>13-valent pneumococcal conjugate vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7-valent pneumococcal conjugate vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7-valent pneumococcal conjugate vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent pneumococcal conjugate vaccine</intervention_name>
    <description>Single 0.5 mL dose given at 2, 3, 4, and 12 months of age.</description>
    <arm_group_label>13-valent pneumococcal conjugate vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>7-valent pneumococcal conjugate vaccine</intervention_name>
    <description>Single 0.5 mL dose given at 2, 3, 4, and 12 months of age.</description>
    <arm_group_label>7-valent pneumococcal conjugate vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentavac</intervention_name>
    <description>The Pentavac was administered by intramuscular injection 0.5 ml into the anterolateral thigh muscle of the right leg at 2, 3, and 4 months (infant series) and 12 months of age (toddler dose).</description>
    <arm_group_label>13-valent pneumococcal conjugate vaccine</arm_group_label>
    <arm_group_label>7-valent pneumococcal conjugate vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy 2-month-old infants.

          -  Available for the entire study period.

        Exclusion criteria:

        · Known contraindication to vaccines.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Days</minimum_age>
    <maximum_age>98 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For France, infomedfrance@wyeth.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Albi</city>
        <zip>81000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amiens</city>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ancenis</city>
        <zip>44150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Blanquefort</city>
        <zip>33370</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bondues</city>
        <zip>59910</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chalons en champagne</city>
        <zip>51000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Draguignan</city>
        <zip>83300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ecully</city>
        <zip>69130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essey-les-nancy</city>
        <zip>54270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Floirac</city>
        <zip>33270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frejus</city>
        <zip>83600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Garges-les-Gonesse</city>
        <zip>95140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Illkirch</city>
        <zip>67400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Joue les tours</city>
        <zip>37300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Le havre</city>
        <zip>76600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Le plessis-trevise</city>
        <zip>94420</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Le pontet</city>
        <zip>84130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Les lilas</city>
        <zip>93260</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Les sables d'olonne</city>
        <zip>85100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Libourne</city>
        <zip>33500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lingolsheim</city>
        <zip>67380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <zip>69005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <zip>69007</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marcq en baroeul</city>
        <zip>59700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maromme</city>
        <zip>76150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moutiers</city>
        <zip>73600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nice</city>
        <zip>06300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nogent sur marne</city>
        <zip>94130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nogent-sur-marne</city>
        <zip>94130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oullins</city>
        <zip>69600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rouen</city>
        <zip>76100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Strasbourg</city>
        <zip>67100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thionville</city>
        <zip>57100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tresses melac</city>
        <zip>33370</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vandoeuvre les nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vaulx-en-velin</city>
        <zip>69120</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Villeneuve d'ascq</city>
        <zip>59650</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vitry-sur-seine</city>
        <zip>94400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2006</study_first_submitted>
  <study_first_submitted_qc>August 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2006</study_first_posted>
  <results_first_submitted>March 26, 2010</results_first_submitted>
  <results_first_submitted_qc>July 6, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 15, 2012</results_first_posted>
  <disposition_first_submitted>February 26, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>September 30, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 1, 2009</disposition_first_posted>
  <last_update_submitted>July 6, 2012</last_update_submitted>
  <last_update_submitted_qc>July 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Vaccine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited in France from October 2006 to July 2007.</recruitment_details>
      <pre_assignment_details>Participants were enrolled into the study according to inclusion/exclusion criteria without a screening period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>13vPnC/13vPnC Vaccine</title>
          <description>Participants received one single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with a vaccine containing diphtheria, tetanus, 2-component pertussis (DTaP), inactivated poliovirus (IPV), and hemophilus influenza type b vaccines (Hib) (Pentavac) at 2, 3, and 4 months of age (infant series) and 12 months of age (toddler dose).</description>
        </group>
        <group group_id="P2">
          <title>7vPnC/7vPnC Vaccine</title>
          <description>Participants received one single 0.5 milliliter (mL) dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with a vaccine containing diphtheria, tetanus, 2-component pertussis (DTaP), inactivated poliovirus (IPV), and hemophilus influenza type b vaccines (Hib) (Pentavac) at 2, 3, and 4 months of age (infant series) and 12 months of age (toddler dose).</description>
        </group>
        <group group_id="P3">
          <title>7vPnC/13vPnC Vaccine</title>
          <description>Participants received one single 0.5 milliliter (mL) dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with a vaccine containing diphtheria, tetanus, 2-component pertussis (DTaP), inactivated poliovirus (IPV), and hemophilus influenza type b vaccines (Hib) (Pentavac) at 2, 3, and 4 months of age (infant series). Participants received one single 0.5 mL dose of 13-valent pneumococcal conjugate vaccine (13vPnC)coadministered with Pentavac at 12 months of age (toddler dose).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Infant Series</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="304"/>
                <participants group_id="P2" count="309"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 1</title>
              <participants_list>
                <participants group_id="P1" count="302"/>
                <participants group_id="P2" count="309"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 2</title>
              <participants_list>
                <participants group_id="P1" count="295"/>
                <participants group_id="P2" count="304"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 3</title>
              <participants_list>
                <participants group_id="P1" count="291"/>
                <participants group_id="P2" count="302"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="290"/>
                <participants group_id="P2" count="299"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to return</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>After Infant</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="290"/>
                <participants group_id="P2" count="299"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="273"/>
                <participants group_id="P2" count="289"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to return</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Toddler Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="273"/>
                <participants group_id="P2" count="152"/>
                <participants group_id="P3" count="137"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="268"/>
                <participants group_id="P2" count="151"/>
                <participants group_id="P3" count="137"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to return</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>13vPnC/13vPnC Vaccine</title>
          <description>Participants received one single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) coadministered with a vaccine containing diphtheria, tetanus, 2-component pertussis (DTaP), inactivated poliovirus (IPV), and hemophilus influenza type b vaccines (Hib) (Pentavac) at 2, 3, and 4 months of age (infant series) and 12 months of age (toddler dose).</description>
        </group>
        <group group_id="B2">
          <title>7vPnC/7vPnC Vaccine</title>
          <description>Participants received one single 0.5 milliliter (mL) dose of 7-valent pneumococcal conjugate vaccine (7vPnC) coadministered with a vaccine containing diphtheria, tetanus, 2-component pertussis (DTaP), inactivated poliovirus (IPV), and hemophilus influenza type b vaccines (Hib) (Pentavac) at 2, 3, and 4 months of age (infant series) and 12 months of age (toddler dose).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="304"/>
            <count group_id="B2" value="309"/>
            <count group_id="B3" value="613"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.1" spread="0.5"/>
                    <measurement group_id="B2" value="2.1" spread="0.5"/>
                    <measurement group_id="B3" value="2.1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="164"/>
                    <measurement group_id="B3" value="333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria, Tetanus, Hemophilus Influenza Type b (Hib), Poliomyelitis (Type 1, 2, 3), Pertussis Toxin (PT) and Filamentous Hemagglutinin (FHA) in 13vPnC Group Relative to 7vPnC Group</title>
        <description>Percentage of participants achieving predefined antibody threshold levels ≥0.1 IU/mL for diphtheria, ≥0.1 IU/mL for tetanus, ≥ 0.15 μg/mL for Hib polyribosylribitol phosphate (PRP), antibody titer ≥1:8 for polio and ≥5 EU/mL for pertussis (PT and FHA) with the corresponding 95% CI for each concomitant antigen are presented.</description>
        <time_frame>One Month After the 3-Dose Infant Series (at 5 months of age) and the Toddler Dose (at 13 months of age)</time_frame>
        <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After the Infant Series</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC After the Infant Series</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC After the Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC After the Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria, Tetanus, Hemophilus Influenza Type b (Hib), Poliomyelitis (Type 1, 2, 3), Pertussis Toxin (PT) and Filamentous Hemagglutinin (FHA) in 13vPnC Group Relative to 7vPnC Group</title>
          <description>Percentage of participants achieving predefined antibody threshold levels ≥0.1 IU/mL for diphtheria, ≥0.1 IU/mL for tetanus, ≥ 0.15 μg/mL for Hib polyribosylribitol phosphate (PRP), antibody titer ≥1:8 for polio and ≥5 EU/mL for pertussis (PT and FHA) with the corresponding 95% CI for each concomitant antigen are presented.</description>
          <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="263"/>
                <count group_id="O3" value="241"/>
                <count group_id="O4" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pertussis - PT Infant ≥5 Toddler 5 (EU/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="98.5" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="97.3" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis - PT Infant ≥26 Toddler 17 (EU/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.3" lower_limit="90.8" upper_limit="96.8"/>
                    <measurement group_id="O2" value="95.0" lower_limit="91.7" upper_limit="97.3"/>
                    <measurement group_id="O3" value="98.3" lower_limit="95.8" upper_limit="99.5"/>
                    <measurement group_id="O4" value="96.2" lower_limit="91.4" upper_limit="98.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis - FHA Infant ≥5 Toddler 5 (EU/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="98.5" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="97.3" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis - FHA Infant ≥7.82 Toddler 7.82 (EU/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="98.5" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="97.3" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis - FHA Infant ≥36.00 Toddler 75 (EU/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.5" lower_limit="89.9" upper_limit="96.2"/>
                    <measurement group_id="O2" value="95.8" lower_limit="92.6" upper_limit="97.9"/>
                    <measurement group_id="O3" value="92.5" lower_limit="88.4" upper_limit="95.5"/>
                    <measurement group_id="O4" value="95.5" lower_limit="90.4" upper_limit="98.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diphtheria 0.1 (IU/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5" lower_limit="70.9" upper_limit="81.5"/>
                    <measurement group_id="O2" value="84.6" lower_limit="79.6" upper_limit="88.7"/>
                    <measurement group_id="O3" value="99.2" lower_limit="97.0" upper_limit="99.9"/>
                    <measurement group_id="O4" value="100" lower_limit="97.3" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diphtheria 0.01 (IU/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="98.5" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="97.3" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus 0.1 (IU/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.9" lower_limit="80.0" upper_limit="89.1"/>
                    <measurement group_id="O2" value="82.2" lower_limit="76.9" upper_limit="86.7"/>
                    <measurement group_id="O3" value="96.2" lower_limit="93.0" upper_limit="98.3"/>
                    <measurement group_id="O4" value="98.5" lower_limit="94.7" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus 0.01 (IU/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="98.6" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="98.5" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="97.3" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio Type 1 (1:8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.8" lower_limit="84.3" upper_limit="92.3"/>
                    <measurement group_id="O2" value="91.0" lower_limit="86.8" upper_limit="94.2"/>
                    <measurement group_id="O3" value="97.9" lower_limit="95.2" upper_limit="99.3"/>
                    <measurement group_id="O4" value="98.4" lower_limit="94.5" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio Type 2 (1:8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.7" lower_limit="72.1" upper_limit="82.6"/>
                    <measurement group_id="O2" value="82.0" lower_limit="76.8" upper_limit="86.5"/>
                    <measurement group_id="O3" value="98.7" lower_limit="96.4" upper_limit="99.7"/>
                    <measurement group_id="O4" value="99.2" lower_limit="95.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio Type 3 (1:8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.6" lower_limit="88.7" upper_limit="95.5"/>
                    <measurement group_id="O2" value="93.0" lower_limit="89.1" upper_limit="95.8"/>
                    <measurement group_id="O3" value="99.2" lower_limit="97.0" upper_limit="99.9"/>
                    <measurement group_id="O4" value="100.0" lower_limit="97.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hib (PRP) 0.15 (μg/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.5" lower_limit="92.1" upper_limit="97.7"/>
                    <measurement group_id="O2" value="94.6" lower_limit="91.0" upper_limit="97.1"/>
                    <measurement group_id="O3" value="100.0" lower_limit="98.5" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="97.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hib (PRP) 1.0 (μg/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6" lower_limit="52.1" upper_limit="64.9"/>
                    <measurement group_id="O2" value="63.1" lower_limit="56.6" upper_limit="69.2"/>
                    <measurement group_id="O3" value="97.9" lower_limit="95.2" upper_limit="99.3"/>
                    <measurement group_id="O4" value="97.7" lower_limit="93.5" upper_limit="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis - PT the difference in percentages between the two groups (13vPnC - 7vPnC) at (≥5 EU/mL) threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis - PTf the difference in percentages between the two groups (13vPnC - 7vPnC) at (≥26.00 EU/mL) threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.8</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis - FHA the difference in percentages between the two groups (13vPnC - 7vPnC) at (≥5 EU/mL) threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis - FHAf the difference in percentages between the two groups (13vPnC - 7vPnC) at (≥36.00 EU/mL) threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.4</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis - FHA the difference in percentages between the two groups (13vPnC - 7vPnC) at (≥7.82 EU/mL) threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Pertussis - PT the difference in percentages between the two groups (13vPnC - 7vPnC) at (5 EU/mL) threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Pertussis - PTf the difference in percentages between the two groups (13vPnC - 7vPnC) at (17.00 EU/mL) threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>6.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Pertussis - FHA the difference in percentages between the two groups (13vPnC - 7vPnC) at (5 EU/mL) threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Pertussis - FHA the difference in percentages between the two groups (13vPnC - 7vPnC) at (7.82 EU/mL) threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Pertussis - FHAf the difference in percentages between the two groups (13vPnC - 7vPnC) at (75.00 EU/mL) threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.0</ci_lower_limit>
            <ci_upper_limit>2.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Diphtheria the difference in percentages between the two groups (13vPnC - 7vPnC) at 0.1 (IU/mL) threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-8.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-14.9</ci_lower_limit>
            <ci_upper_limit>-1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Diphtheria the difference in percentages between the two groups (13vPnC - 7vPnC) at 0.01 (IU/mL) threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Tetanus the difference in percentages between the two groups (13vPnC - 7vPnC) at 0.1 (IU/mL) threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>9.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Tetanus the difference in percentages between the two groups (13vPnC - 7vPnC) at 0.01 (IU/mL) threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Diphtheria the difference in percentages between the two groups (13vPnC - 7vPnC) at 0.1 (IU/mL) threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Diphtheria the difference in percentages between the two groups (13vPnC - 7vPnC) at 0.01 (IU/mL) threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Tetanus the difference in percentages between the two groups (13vPnC - 7vPnC) at 0.1 (IU/mL) threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.8</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Tetanus the difference in percentages between the two groups (13vPnC - 7vPnC) at 0.01 (IU/mL) threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Polio Type 1 the difference in percentages between the two groups (13vPnC - 7vPnC) at (1:8) threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-7.6</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Polio Type 2 the difference in percentages between the two groups (13vPnC - 7vPnC) at (1:8) threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-4.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-11.4</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Polio Type 3 the difference in percentages between the two groups (13vPnC - 7vPnC) at (1:8) threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.0</ci_lower_limit>
            <ci_upper_limit>4.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Polio Type 1 the difference in percentages between the two groups (13vPnC - 7vPnC) at (1:8) threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.6</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Polio Type 2 the difference in percentages between the two groups (13vPnC - 7vPnC) at (1:8) threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Polio Type 3 the difference in percentages between the two groups (13vPnC - 7vPnC) at (1:8) threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Hib (PRP) the difference in percentages between the two groups (13vPnC - 7vPnC) at 0.15 (μg/mL) threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.2</ci_lower_limit>
            <ci_upper_limit>5.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Hib (PRP) the difference in percentages between the two groups (13vPnC - 7vPnC) at 1.0 (μg/mL) threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-4.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-13.2</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Hib (PRP) the difference in percentages between the two groups (13vPnC - 7vPnC) at 0.15 (μg/mL) threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>2.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Hib (PRP) the difference in percentages between the two groups (13vPnC - 7vPnC) at 1.0 (μg/mL) threshold was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lowest limit of 2-sided 95% CI for the difference between the 2 groups (13vPnC - 7vPnC) &gt; -10%.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Pneumococcal Antibody Level ≥0.35µg/mL (ELISA) After the Toddler Dose in the 13vPnC/13vPnC, 7vPnC/7vPnC and 7vPnC/13vPnC Groups</title>
        <description>Percentages of participants achieving World health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>One month after the toddler dose (at 13 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (n) = number of participants with a determinate antibody concentration for the specified serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Infant Series / 13vPnC Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC Infant Series / 7vPnC Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O3">
            <title>7vPnC Infant Series / 13vPnC Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Pentavac at 2, 3, and 4 months. One single 0.5 mL dose of 13vPnC was coadministered with Pentavac at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Pneumococcal Antibody Level ≥0.35µg/mL (ELISA) After the Toddler Dose in the 13vPnC/13vPnC, 7vPnC/7vPnC and 7vPnC/13vPnC Groups</title>
          <description>Percentages of participants achieving World health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>Evaluable immunogenicity (per protocol) population who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (n) = number of participants with a determinate antibody concentration for the specified serotype.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotypes - Serotype 4 (n=233,126,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99.1" lower_limit="95.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 6B (n=233,126,108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="97.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.2" lower_limit="95.7" upper_limit="100.0"/>
                    <measurement group_id="O3" value="98.1" lower_limit="93.5" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 9V (n=232,124,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="96.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 14 (n=233,135,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="97.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99.1" lower_limit="95.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 18C (n=230,125,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="97.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.2" lower_limit="95.6" upper_limit="100.0"/>
                    <measurement group_id="O3" value="98.2" lower_limit="93.8" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 19F (n=233,126,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.9" lower_limit="95.1" upper_limit="99.3"/>
                    <measurement group_id="O2" value="97.6" lower_limit="93.2" upper_limit="99.5"/>
                    <measurement group_id="O3" value="97.3" lower_limit="92.4" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 23F (n=232,123,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="97.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.2" lower_limit="95.6" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99.1" lower_limit="95.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 1 (n=233,119,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.0" upper_limit="4.6"/>
                    <measurement group_id="O3" value="95.5" lower_limit="89.9" upper_limit="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 3 (n=233,124,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.8" lower_limit="91.2" upper_limit="97.3"/>
                    <measurement group_id="O2" value="13.7" lower_limit="8.2" upper_limit="21.0"/>
                    <measurement group_id="O3" value="93.8" lower_limit="87.7" upper_limit="97.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 5 (n=236,111,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="73.0" lower_limit="63.7" upper_limit="81.0"/>
                    <measurement group_id="O3" value="90.1" lower_limit="83.0" upper_limit="94.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 6A (n=235,124,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="89.5" lower_limit="82.7" upper_limit="94.3"/>
                    <measurement group_id="O3" value="89.9" lower_limit="82.7" upper_limit="94.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 7F (n=234,124,110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="7.3" lower_limit="3.4" upper_limit="13.3"/>
                    <measurement group_id="O3" value="100.0" lower_limit="96.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 19A(n=233,127,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="96.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 4 the difference in percentages between the two groups (13vPnC Infant Series / 13vPnC Toddler Dose - 7vPnC Infant Series / 7vPnC Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For serotype 4 the difference in percentages between the two groups (13vPnC Infant Series / 13vPnC Toddler Dose - 7vPnC Infant Series / 13vPnC Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>4.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For serotype 4 the difference in percentages between the two groups (7vPnC Infant Series / 13vPnC Toddler Dose - 7vPnC Infant Series / 7vPnC Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.9</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 6B the difference in percentages between the two groups (13vPnC Infant Series / 13vPnC Toddler Dose - 7vPnC Infant Series / 7vPnC Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>3.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For serotype 6B the difference in percentages between the two groups (13vPnC Infant Series / 13vPnC Toddler Dose - 7vPnC Infant Series / 13vPnC Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>5.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For serotype 6B the difference in percentages between the two groups (7vPnC Infant Series / 13vPnC Toddler Dose - 7vPnC Infant Series / 7vPnC Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.8</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 9V the difference in percentages between the two groups (13vPnC Infant Series / 13vPnC Toddler Dose - 7vPnC Infant Series / 7vPnC Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For serotype 9V the difference in percentages between the two groups (13vPnC Infant Series / 13vPnC Toddler Dose - 7vPnC Infant Series / 13vPnC Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For serotype 9V the difference in percentages between the two groups (7vPnC Infant Series / 13vPnC Toddler Dose - 7vPnC Infant Series / 7vPnC Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 14 the difference in percentages between the two groups (13vPnC Infant Series / 13vPnC Toddler Dose - 7vPnC Infant Series / 7vPnC Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For serotype 14 the difference in percentages between the two groups (13vPnC Infant Series / 13vPnC Toddler Dose - 7vPnC Infant Series / 13vPnC Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For serotype 14 the difference in percentages between the two groups (7vPnC Infant Series / 13vPnC Toddler Dose - 7vPnC Infant Series / 7vPnC Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.9</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 18C the difference in percentages between the two groups (13vPnC Infant Series / 13vPnC Toddler Dose - 7vPnC Infant Series / 7vPnC Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>3.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For serotype 18C the difference in percentages between the two groups (13vPnC Infant Series / 13vPnC Toddler Dose - 7vPnC Infant Series / 13vPnC Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>5.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For serotype 18C the difference in percentages between the two groups (7vPnC Infant Series / 13vPnC Toddler Dose - 7vPnC Infant Series / 7vPnC Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.5</ci_lower_limit>
            <ci_upper_limit>2.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 19F the difference in percentages between the two groups (13vPnC Infant Series / 13vPnC Toddler Dose - 7vPnC Infant Series / 7vPnC Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>4.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For serotype 19F the difference in percentages between the two groups (13vPnC Infant Series / 13vPnC Toddler Dose - 7vPnC Infant Series / 13vPnC Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>5.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For serotype 19F the difference in percentages between the two groups (7vPnC Infant Series / 13vPnC Toddler Dose - 7vPnC Infant Series / 7vPnC Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.5</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For serotype 23F the difference in percentages between the two groups (13vPnC Infant Series / 13vPnC Toddler Dose - 7vPnC Infant Series / 7vPnC Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For serotype 23F the difference in percentages between the two groups (13vPnC Infant Series / 13vPnC Toddler Dose - 7vPnC Infant Series / 13vPnC Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For serotype 23F the difference in percentages between the two groups (7vPnC Infant Series / 13vPnC Toddler Dose - 7vPnC Infant Series / 7vPnC Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.1</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pneumococcal Geometric Mean Concentration (GMC) Before and After the Toddler Dose in the 13vPnC/13vPnC, 7vPnC/7vPnC and 7vPnC/13vPnC Groups</title>
        <description>Antibody GMC as measured by ELISA for 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>One month after the Toddler Dose (at 13 months of age)</time_frame>
        <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC/13vPnC Before Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>13vPnC/13vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series) and 12 months of age (toddler dose), assessment made at 13 months of age.</description>
          </group>
          <group group_id="O3">
            <title>7vPnC/7vPnC Before Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC/7vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series) and 12 months of age (toddler dose), assessment made at 13 months of age.</description>
          </group>
          <group group_id="O5">
            <title>7vPnC/13vPnC Before Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Pentavac at 2, 3, and 4 months of age (infant series). Participants recieved one single 0.5 mL dose of 13vPnC coadministered with Pentavac at 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O6">
            <title>7vPnC/13vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Pentavac at 2, 3, and 4 months of age (infant series). Participants received one single 0.5 mL dose of 13vPnC coadministered with Pentavac at 12 months of age (toddler dose), assessment made at 13 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Pneumococcal Geometric Mean Concentration (GMC) Before and After the Toddler Dose in the 13vPnC/13vPnC, 7vPnC/7vPnC and 7vPnC/13vPnC Groups</title>
          <description>Antibody GMC as measured by ELISA for 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="241"/>
                <count group_id="O3" value="133"/>
                <count group_id="O4" value="133"/>
                <count group_id="O5" value="121"/>
                <count group_id="O6" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common - Serotype 4 (n=239,233,131,126,118,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.3" upper_limit="0.3"/>
                    <measurement group_id="O2" value="4.2" lower_limit="3.8" upper_limit="4.7"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.4" upper_limit="0.5"/>
                    <measurement group_id="O4" value="4.8" lower_limit="4.2" upper_limit="5.6"/>
                    <measurement group_id="O5" value="0.5" lower_limit="0.4" upper_limit="0.5"/>
                    <measurement group_id="O6" value="4.0" lower_limit="3.4" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common - Serotype 6B (n=235,233,131,126,115,108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.9" upper_limit="1.1"/>
                    <measurement group_id="O2" value="9.0" lower_limit="8.0" upper_limit="10.1"/>
                    <measurement group_id="O3" value="1.1" lower_limit="0.9" upper_limit="1.3"/>
                    <measurement group_id="O4" value="9.6" lower_limit="8.3" upper_limit="11.2"/>
                    <measurement group_id="O5" value="0.9" lower_limit="0.8" upper_limit="1.1"/>
                    <measurement group_id="O6" value="10.3" lower_limit="8.2" upper_limit="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common - Serotype 9V (n=239,232,131,124,118,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.4" upper_limit="0.5"/>
                    <measurement group_id="O2" value="2.3" lower_limit="2.3" upper_limit="2.8"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.5" upper_limit="0.6"/>
                    <measurement group_id="O4" value="3.2" lower_limit="2.8" upper_limit="3.7"/>
                    <measurement group_id="O5" value="0.4" lower_limit="0.4" upper_limit="0.5"/>
                    <measurement group_id="O6" value="2.3" lower_limit="2.0" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common - Serotype 14 (n=238,233,131,125,118,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.8" upper_limit="2.3"/>
                    <measurement group_id="O2" value="9.5" lower_limit="8.5" upper_limit="10.6"/>
                    <measurement group_id="O3" value="2.4" lower_limit="2.1" upper_limit="2.9"/>
                    <measurement group_id="O4" value="10.8" lower_limit="9.4" upper_limit="12.5"/>
                    <measurement group_id="O5" value="2.4" lower_limit="2.0" upper_limit="3.0"/>
                    <measurement group_id="O6" value="7.8" lower_limit="6.6" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common - Serotype 18C (n=239,230,131,125,118,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.3" upper_limit="0.3"/>
                    <measurement group_id="O2" value="2.3" lower_limit="2.1" upper_limit="2.5"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.3" upper_limit="0.4"/>
                    <measurement group_id="O4" value="2.8" lower_limit="2.5" upper_limit="3.2"/>
                    <measurement group_id="O5" value="0.3" lower_limit="0.3" upper_limit="0.4"/>
                    <measurement group_id="O6" value="2.4" lower_limit="2.0" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common - Serotype 19F (n=239,233,130,126,118,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.6" upper_limit="0.7"/>
                    <measurement group_id="O2" value="5.2" lower_limit="4.5" upper_limit="6.0"/>
                    <measurement group_id="O3" value="0.7" lower_limit="0.6" upper_limit="0.9"/>
                    <measurement group_id="O4" value="4.1" lower_limit="3.4" upper_limit="5.0"/>
                    <measurement group_id="O5" value="0.6" lower_limit="0.5" upper_limit="0.7"/>
                    <measurement group_id="O6" value="3.7" lower_limit="3.0" upper_limit="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common - Serotype 23F (n=237,232,130,123,118,111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.2" upper_limit="0.3"/>
                    <measurement group_id="O2" value="3.0" lower_limit="2.7" upper_limit="3.4"/>
                    <measurement group_id="O3" value="0.3" lower_limit="0.3" upper_limit="0.4"/>
                    <measurement group_id="O4" value="3.7" lower_limit="3.1" upper_limit="4.3"/>
                    <measurement group_id="O5" value="0.3" lower_limit="0.2" upper_limit="0.4"/>
                    <measurement group_id="O6" value="3.1" lower_limit="2.6" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional-Serotype 1 (n=239,233,128,119,116,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.4" upper_limit="0.5"/>
                    <measurement group_id="O2" value="4.1" lower_limit="3.7" upper_limit="4.5"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O6" value="1.8" lower_limit="1.5" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional-Serotype 3 (n=232,233,128,124,115,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.2" upper_limit="0.2"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.9" upper_limit="1.1"/>
                    <measurement group_id="O3" value="0.1" lower_limit="0.1" upper_limit="0.1"/>
                    <measurement group_id="O4" value="0.1" lower_limit="0.1" upper_limit="0.1"/>
                    <measurement group_id="O5" value="0.1" lower_limit="0.1" upper_limit="0.1"/>
                    <measurement group_id="O6" value="1.3" lower_limit="1.1" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional-Serotype 5 (n=236,236,128,124,115,113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.7" upper_limit="0.9"/>
                    <measurement group_id="O2" value="3.3" lower_limit="3.0" upper_limit="3.7"/>
                    <measurement group_id="O3" value="0.4" lower_limit="0.4" upper_limit="0.5"/>
                    <measurement group_id="O4" value="0.5" lower_limit="0.4" upper_limit="0.6"/>
                    <measurement group_id="O5" value="0.4" lower_limit="0.4" upper_limit="0.5"/>
                    <measurement group_id="O6" value="1.1" lower_limit="1.0" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional-Serotype 6A (n=238,235,122,124,116,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.8" upper_limit="1.0"/>
                    <measurement group_id="O2" value="6.1" lower_limit="5.5" upper_limit="6.8"/>
                    <measurement group_id="O3" value="0.4" lower_limit="0.3" upper_limit="0.5"/>
                    <measurement group_id="O4" value="1.5" lower_limit="1.3" upper_limit="1.9"/>
                    <measurement group_id="O5" value="0.4" lower_limit="0.3" upper_limit="0.4"/>
                    <measurement group_id="O6" value="2.6" lower_limit="2.0" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional-Serotype 7F (n=239,234,131,124,117,110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.7" upper_limit="0.9"/>
                    <measurement group_id="O2" value="4.5" lower_limit="4.1" upper_limit="5.0"/>
                    <measurement group_id="O3" value="0.1" lower_limit="0.0" upper_limit="0.1"/>
                    <measurement group_id="O4" value="0.1" lower_limit="0.0" upper_limit="0.1"/>
                    <measurement group_id="O5" value="0.1" lower_limit="0.1" upper_limit="0.1"/>
                    <measurement group_id="O6" value="3.7" lower_limit="3.2" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional-Serotype 19A(n=237,233,131,127,117,112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.3" upper_limit="1.7"/>
                    <measurement group_id="O2" value="9.5" lower_limit="8.5" upper_limit="10.6"/>
                    <measurement group_id="O3" value="1.1" lower_limit="0.9" upper_limit="1.3"/>
                    <measurement group_id="O4" value="4.0" lower_limit="3.5" upper_limit="4.5"/>
                    <measurement group_id="O5" value="0.9" lower_limit="0.7" upper_limit="1.1"/>
                    <measurement group_id="O6" value="5.3" lower_limit="4.6" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For serotype 4 after the toddler dose the GMC ratio (13vPnC Infant Series/13vPnC Toddler Dose After Toddler Dose / 7vPnC Infant Series/7vPnC Toddler Dose After Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>For serotype 4 after the toddler dose the GMC ratio (7vPnC Infant Series/13vPnC Toddler Dose After Toddler Dose / 7vPnC Infant Series/7vPnC Toddler Dose After Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>For serotype 4 after the toddler dose the GMC ratio (13vPnC Infant Series/13vPnC Toddler Dose After Toddler Dose / 7vPnC Infant Series/13vPnC Toddler Dose After Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For serotype 6B after the toddler dose the GMC ratio (13vPnC Infant Series/13vPnC Toddler Dose After Toddler Dose / 7vPnC Infant Series/7vPnC Toddler Dose After Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>For serotype 6B after the toddler dose the GMC ratio (7vPnC Infant Series/13vPnC Toddler Dose After Toddler Dose / 7vPnC Infant Series/7vPnC Toddler Dose After Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>For serotype 6B after the toddler dose the GMC ratio (13vPnC Infant Series/13vPnC Toddler Dose After Toddler Dose / 7vPnC Infant Series/13vPnC Toddler Dose After Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For serotype 9V after the toddler dose the GMC ratio (13vPnC Infant Series/13vPnC Toddler Dose After Toddler Dose / 7vPnC Infant Series/7vPnC Toddler Dose After Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>For serotype 9V after the toddler dose the GMC ratio (7vPnC Infant Series/13vPnC Toddler Dose After Toddler Dose / 7vPnC Infant Series/7vPnC Toddler Dose After Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>For serotype 9V after the toddler dose the GMC ratio (13vPnC Infant Series/13vPnC Toddler Dose After Toddler Dose / 7vPnC Infant Series/13vPnC Toddler Dose After Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For serotype 14 after the toddler dose the GMC ratio (13vPnC Infant Series/13vPnC Toddler Dose After Toddler Dose / 7vPnC Infant Series/7vPnC Toddler Dose After Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>For serotype 14 after the toddler dose the GMC ratio (7vPnC Infant Series/13vPnC Toddler Dose After Toddler Dose / 7vPnC Infant Series/7vPnC Toddler Dose After Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>For serotype 14 after the toddler dose the GMC ratio (13vPnC Infant Series/13vPnC Toddler Dose After Toddler Dose / 7vPnC Infant Series/13vPnC Toddler Dose After Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>1.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>1.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For serotype 18C after the toddler dose the GMC ratio (13vPnC Infant Series/13vPnC Toddler Dose After Toddler Dose / 7vPnC Infant Series/7vPnC Toddler Dose After Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>For serotype 18C after the toddler dose the GMC ratio (7vPnC Infant Series/13vPnC Toddler Dose After Toddler Dose / 7vPnC Infant Series/7vPnC Toddler Dose After Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>For serotype 18C after the toddler dose the GMC ratio (13vPnC Infant Series/13vPnC Toddler Dose After Toddler Dose / 7vPnC Infant Series/13vPnC Toddler Dose After Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For serotype 19F after the toddler dose the GMC ratio (13vPnC Infant Series/13vPnC Toddler Dose After Toddler Dose / 7vPnC Infant Series/7vPnC Toddler Dose After Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>1.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>For serotype 19F after the toddler dose the GMC ratio (7vPnC Infant Series/13vPnC Toddler Dose After Toddler Dose / 7vPnC Infant Series/7vPnC Toddler Dose After Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>For serotype 19F after the toddler dose the GMC ratio (13vPnC Infant Series/13vPnC Toddler Dose After Toddler Dose / 7vPnC Infant Series/13vPnC Toddler Dose After Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>1.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.08</ci_lower_limit>
            <ci_upper_limit>1.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For serotype 23F after the toddler dose the GMC ratio (13vPnC Infant Series/13vPnC Toddler Dose After Toddler Dose / 7vPnC Infant Series/7vPnC Toddler Dose After Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>For serotype 23F after the toddler dose the GMC ratio (7vPnC Infant Series/13vPnC Toddler Dose After Toddler Dose / 7vPnC Infant Series/7vPnC Toddler Dose After Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>For serotype 23F after the toddler dose the GMC ratio (13vPnC Infant Series/13vPnC Toddler Dose After Toddler Dose / 7vPnC Infant Series/13vPnC Toddler Dose After Toddler Dose) was calculated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Antibody Titer ≥1:8 After the Toddler Dose in 13vPnC/13vPnC and 7vPnC/13vPnC Groups</title>
        <description>Percentage of participants achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>One month after the toddler dose (at 13 months of age)</time_frame>
        <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC/13vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC/13vPnC After Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Pentavac at 2, 3, and 4 months of age (infant series). Participants received one single 0.5 mL dose of 13vPnC coadministered with Pentavac at 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Antibody Titer ≥1:8 After the Toddler Dose in 13vPnC/13vPnC and 7vPnC/13vPnC Groups</title>
          <description>Percentage of participants achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Additional Serotypes - Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="98.9" lower_limit="94.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="97.8" lower_limit="92.2" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="97.8" lower_limit="92.2" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="98.9" lower_limit="94.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="95.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8" lower_limit="93.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="97.8" lower_limit="92.2" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer (GMT) in 13vPnC/13vPnC and 7vPnC/13vPnC Groups After the Toddler Dose</title>
        <description>GMT as measured by opsonophagocytic activity assay (OPA) for 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>One month after the toddler dose (at 13 months of age)</time_frame>
        <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC/13vPnC After Toddler Dose</title>
            <description>Subjects received one single 0.5 mL dose of 13vPnC coadministered with Pentavac at 2, 3, 4, and 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>7vPnC/13vPnC After Toddler Dose</title>
            <description>Subjects received one single 0.5 mL dose of 7vPnC coadministered with Pentavac at 2, 3, and 4 months. One single 0.5 mL dose of 13vPnC was coadministered with Pentavac at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) in 13vPnC/13vPnC and 7vPnC/13vPnC Groups After the Toddler Dose</title>
          <description>GMT as measured by opsonophagocytic activity assay (OPA) for 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Additional Serotypes - Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.00" lower_limit="99.87" upper_limit="158.97"/>
                    <measurement group_id="O2" value="61.58" lower_limit="47.72" upper_limit="79.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="345.33" lower_limit="296.06" upper_limit="402.80"/>
                    <measurement group_id="O2" value="428.88" lower_limit="346.69" upper_limit="530.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244.18" lower_limit="200.14" upper_limit="297.92"/>
                    <measurement group_id="O2" value="130.99" lower_limit="103.68" upper_limit="165.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1346.83" lower_limit="1143.98" upper_limit="1585.65"/>
                    <measurement group_id="O2" value="891.44" lower_limit="694.76" upper_limit="1143.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8126.24" lower_limit="6657.36" upper_limit="9919.21"/>
                    <measurement group_id="O2" value="17034.59" lower_limit="14316.59" upper_limit="20268.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="804.06" lower_limit="615.90" upper_limit="1049.71"/>
                    <measurement group_id="O2" value="1072.43" lower_limit="799.06" upper_limit="1439.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration (GMC) as Measured by Enzyme-linked Immunosorbent Assay (ELISA) for Diphtheria Toxoid and Tetanus Toxoid in 13vPnC Group Relative to 7vPnC Group</title>
        <time_frame>One month after the 3-Dose Infant Series (at 5 months of age) and the Toddler Dose (at 13 months of age)</time_frame>
        <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After the Infant Series</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC After the Infant Series</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC After the Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC After the Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a vaccine containing Pentavac at 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) as Measured by Enzyme-linked Immunosorbent Assay (ELISA) for Diphtheria Toxoid and Tetanus Toxoid in 13vPnC Group Relative to 7vPnC Group</title>
          <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="263"/>
                <count group_id="O3" value="241"/>
                <count group_id="O4" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diphtheria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" lower_limit="0.17" upper_limit="0.21"/>
                    <measurement group_id="O2" value="0.24" lower_limit="0.22" upper_limit="0.27"/>
                    <measurement group_id="O3" value="2.09" lower_limit="1.87" upper_limit="2.34"/>
                    <measurement group_id="O4" value="2.60" lower_limit="2.26" upper_limit="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" lower_limit="0.18" upper_limit="0.22"/>
                    <measurement group_id="O2" value="0.21" lower_limit="0.19" upper_limit="0.23"/>
                    <measurement group_id="O3" value="1.08" lower_limit="0.94" upper_limit="1.24"/>
                    <measurement group_id="O4" value="1.25" lower_limit="1.05" upper_limit="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Diphtheria the GMC ratio was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Tetanus the GMC ratio was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Diphtheria the GMC ratio was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Tetanus the GMC ratio was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration (GMC) for Haemophilus Influenzae Type b (Hib) in 13vPnC Group Relative to 7vPnC Group</title>
        <time_frame>One month after the 3-Dose Infant Series (at 5 months of age) and the Toddler Dose (at 13 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After the Infant Series</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC After the Infant Series</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC After the Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC After the Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) for Haemophilus Influenzae Type b (Hib) in 13vPnC Group Relative to 7vPnC Group</title>
          <population>Evaluable immunogenicity (per protocol) population adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>μg/mL</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="241"/>
                <count group_id="O3" value="240"/>
                <count group_id="O4" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" lower_limit="1.10" upper_limit="1.49"/>
                    <measurement group_id="O2" value="1.40" lower_limit="1.19" upper_limit="1.64"/>
                    <measurement group_id="O3" value="12.15" lower_limit="10.54" upper_limit="14.00"/>
                    <measurement group_id="O4" value="11.68" lower_limit="9.66" upper_limit="14.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Hib (PRP) the GMC ratio was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Hib (PRP) the GMC ratio was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration (GMC) as Measured by Enzyme-linked Immunosorbent Assay (ELISA) for Poliomyelitis (Type 1, Type 2 and Type 3) in 13vPnC Group Relative to 7vPnC Group</title>
        <time_frame>One month after the 3-Dose Infant Series (at 5 months of age) and the Toddler Dose (at 13 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After the Infant Series</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC After the Infant Series</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC After the Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC After the Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) as Measured by Enzyme-linked Immunosorbent Assay (ELISA) for Poliomyelitis (Type 1, Type 2 and Type 3) in 13vPnC Group Relative to 7vPnC Group</title>
          <population>Evaluable immunogenicity (per protocol) population adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>titer</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="256"/>
                <count group_id="O3" value="239"/>
                <count group_id="O4" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Polio Type 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.99" lower_limit="21.37" upper_limit="29.23"/>
                    <measurement group_id="O2" value="28.33" lower_limit="24.40" upper_limit="32.89"/>
                    <measurement group_id="O3" value="253.05" lower_limit="207.15" upper_limit="309.11"/>
                    <measurement group_id="O4" value="250.56" lower_limit="193.17" upper_limit="324.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio Type 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.75" lower_limit="15.07" upper_limit="20.92"/>
                    <measurement group_id="O2" value="21.55" lower_limit="18.43" upper_limit="25.20"/>
                    <measurement group_id="O3" value="408.34" lower_limit="338.94" upper_limit="491.95"/>
                    <measurement group_id="O4" value="415.20" lower_limit="325.57" upper_limit="529.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio Type 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.08" lower_limit="34.08" upper_limit="49.52"/>
                    <measurement group_id="O2" value="52.95" lower_limit="43.26" upper_limit="64.82"/>
                    <measurement group_id="O3" value="536.32" lower_limit="436.46" upper_limit="659.02"/>
                    <measurement group_id="O4" value="638.18" lower_limit="501.50" upper_limit="812.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Polio Type 1 the GMC ratio was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Polio Type 2 the GMC ratio was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Polio Type 3 the GMC ratio was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Polio Type 1 the GMC ratio was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Polio Type 2 the GMC ratio was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Polio Type 3 the GMC ratio was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration (GMC) as Measured by ELISA for Pertussis Toxin (PT) and Pertussis Filamentous Hemagglutinin (FHA) in 13vPnC Group Relative to 7vPnC Group</title>
        <time_frame>One month after the 3-Dose Infant Series (at 5 months of age) and the Toddler Dose (at 13 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC After the Infant Series</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC After the Infant Series</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC After the Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC After the Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) as Measured by ELISA for Pertussis Toxin (PT) and Pertussis Filamentous Hemagglutinin (FHA) in 13vPnC Group Relative to 7vPnC Group</title>
          <population>Evaluable immunogenicity (per protocol) population adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations.</population>
          <units>EU/mL</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="262"/>
                <count group_id="O3" value="239"/>
                <count group_id="O4" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pertussis - FHA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.12" lower_limit="89.84" upper_limit="104.98"/>
                    <measurement group_id="O2" value="111.23" lower_limit="102.80" upper_limit="120.35"/>
                    <measurement group_id="O3" value="204.28" lower_limit="185.65" upper_limit="224.79"/>
                    <measurement group_id="O4" value="241.08" lower_limit="210.92" upper_limit="275.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis - PT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.94" lower_limit="58.80" upper_limit="67.38"/>
                    <measurement group_id="O2" value="68.20" lower_limit="63.60" upper_limit="73.14"/>
                    <measurement group_id="O3" value="61.09" lower_limit="56.19" upper_limit="66.40"/>
                    <measurement group_id="O4" value="61.70" lower_limit="54.55" upper_limit="69.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis - FHA the GMC ratio was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For Pertussis - PT the GMC ratio was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Pertussis - FHA the GMC ratio was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Pertussis - PT the GMC ratio was calculated</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority for concomitant antigens was declared if the lower bound of the 2-sided, 95% CI for the GMC ratio (13vPnC group/7vPnC group) was &gt;0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving a Pneumococcal Antibody Level ≥0.35µg/mL (ELISA) After the 3-Dose Infant Series of 13vPnC</title>
        <description>Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
        <time_frame>One month after the 3-Dose Infant Series (at 5 months of age)</time_frame>
        <population>Evaluable immunogenicity (per protocol) population adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (n) = number of participants with a determinate immunoglobulin G (IgG) antibody concentration to the given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Pneumococcal Antibody Level ≥0.35µg/mL (ELISA) After the 3-Dose Infant Series of 13vPnC</title>
          <description>Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.</description>
          <population>Evaluable immunogenicity (per protocol) population adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (n) = number of participants with a determinate immunoglobulin G (IgG) antibody concentration to the given serotype.</population>
          <units>percentage of participants</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotypes - Serotype 4 (n=244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.4" lower_limit="87.1" upper_limit="94.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 6B (n=241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.6" lower_limit="66.5" upper_limit="78.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 9V (n=238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.9" lower_limit="88.8" upper_limit="95.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 14 (n=236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.9" lower_limit="91.3" upper_limit="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 18C (n=242)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.5" lower_limit="86.1" upper_limit="93.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 19F (n=241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.9" lower_limit="95.2" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 23F (n=244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.8" lower_limit="77.5" upper_limit="87.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 1 (n=240)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.8" lower_limit="86.5" upper_limit="94.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 3 (n=242)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.3" lower_limit="93.1" upper_limit="98.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 5 (n=243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.0" lower_limit="78.7" upper_limit="88.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 6A (n=243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.6" lower_limit="80.5" upper_limit="89.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 7F (n=238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5" lower_limit="94.6" upper_limit="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 19A (n=244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5" lower_limit="94.7" upper_limit="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Pre-Specified Local Reactions</title>
        <description>Local reactions were collected using an electronic diary. Tenderness (Tender)was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (Sev) (&gt;7.0 cm). Participants may be represented in more than 1 category.</description>
        <time_frame>During the 4-day period after each dose</time_frame>
        <population>The safety population included all participants who received at least 1 dose of vaccine, (n) = number of participants reporting yes for at least 1 day or no for all days.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Dose 1</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 2 months of age (infant series).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC Dose 1</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a vaccine containing Pentavac at 2 months of age (infant series).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 3 months of age (infant series).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a vaccine containing Pentavac at 3 months of age (infant series).</description>
          </group>
          <group group_id="O5">
            <title>13vPnC Dose 3</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 4 months of age (infant series).</description>
          </group>
          <group group_id="O6">
            <title>7vPnC Dose 3</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a vaccine containing Pentavac at 4 months of age (infant series).</description>
          </group>
          <group group_id="O7">
            <title>13vPnC/13vPnC Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O8">
            <title>7vPnC/7vPnC Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a vaccine containing Pentavac at 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O9">
            <title>7vPnC/13vPnC Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Local Reactions</title>
          <description>Local reactions were collected using an electronic diary. Tenderness (Tender)was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (Sev) (&gt;7.0 cm). Participants may be represented in more than 1 category.</description>
          <population>The safety population included all participants who received at least 1 dose of vaccine, (n) = number of participants reporting yes for at least 1 day or no for all days.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="309"/>
                <count group_id="O3" value="302"/>
                <count group_id="O4" value="309"/>
                <count group_id="O5" value="302"/>
                <count group_id="O6" value="309"/>
                <count group_id="O7" value="273"/>
                <count group_id="O8" value="152"/>
                <count group_id="O9" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tender-Any (n=256,257,223,225,210,206,189,96,89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3"/>
                    <measurement group_id="O2" value="38.5"/>
                    <measurement group_id="O3" value="33.2"/>
                    <measurement group_id="O4" value="42.2"/>
                    <measurement group_id="O5" value="36.2"/>
                    <measurement group_id="O6" value="32.0"/>
                    <measurement group_id="O7" value="50.3"/>
                    <measurement group_id="O8" value="44.8"/>
                    <measurement group_id="O9" value="64.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tender-Sig (n=237,245,203,208,188,193,155,86,75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5"/>
                    <measurement group_id="O2" value="4.9"/>
                    <measurement group_id="O3" value="5.4"/>
                    <measurement group_id="O4" value="6.7"/>
                    <measurement group_id="O5" value="3.7"/>
                    <measurement group_id="O6" value="3.1"/>
                    <measurement group_id="O7" value="5.2"/>
                    <measurement group_id="O8" value="4.7"/>
                    <measurement group_id="O9" value="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling-Any (n=254,256,226,235,217,219,185,99,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.3"/>
                    <measurement group_id="O2" value="38.7"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="54.5"/>
                    <measurement group_id="O5" value="48.4"/>
                    <measurement group_id="O6" value="51.1"/>
                    <measurement group_id="O7" value="53.5"/>
                    <measurement group_id="O8" value="57.6"/>
                    <measurement group_id="O9" value="59.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling-Mild(n=249,255,223,232,213,214,181,99,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.9"/>
                    <measurement group_id="O2" value="35.7"/>
                    <measurement group_id="O3" value="46.6"/>
                    <measurement group_id="O4" value="51.3"/>
                    <measurement group_id="O5" value="44.6"/>
                    <measurement group_id="O6" value="45.8"/>
                    <measurement group_id="O7" value="48.1"/>
                    <measurement group_id="O8" value="55.6"/>
                    <measurement group_id="O9" value="57.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling-Mod (n=243,246,207,208,193,194,159,88,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4"/>
                    <measurement group_id="O2" value="9.3"/>
                    <measurement group_id="O3" value="14.0"/>
                    <measurement group_id="O4" value="14.4"/>
                    <measurement group_id="O5" value="14.0"/>
                    <measurement group_id="O6" value="16.0"/>
                    <measurement group_id="O7" value="19.5"/>
                    <measurement group_id="O8" value="15.9"/>
                    <measurement group_id="O9" value="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling-Sev (n=235,244,199,203,184,188,152,87,73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.7"/>
                    <measurement group_id="O8" value="0.0"/>
                    <measurement group_id="O9" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness-Any (n=256,260,236,241,226,223,187,106,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.5"/>
                    <measurement group_id="O2" value="46.9"/>
                    <measurement group_id="O3" value="53.4"/>
                    <measurement group_id="O4" value="58.1"/>
                    <measurement group_id="O5" value="55.8"/>
                    <measurement group_id="O6" value="59.2"/>
                    <measurement group_id="O7" value="66.8"/>
                    <measurement group_id="O8" value="60.4"/>
                    <measurement group_id="O9" value="63.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness-Mild(n=252,259,234,240,223,221,180,106,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9"/>
                    <measurement group_id="O2" value="45.6"/>
                    <measurement group_id="O3" value="50.9"/>
                    <measurement group_id="O4" value="56.7"/>
                    <measurement group_id="O5" value="52.5"/>
                    <measurement group_id="O6" value="55.7"/>
                    <measurement group_id="O7" value="60.0"/>
                    <measurement group_id="O8" value="54.7"/>
                    <measurement group_id="O9" value="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness-Mod (n=241,245,205,206,190,192,165,87,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="3.7"/>
                    <measurement group_id="O3" value="7.3"/>
                    <measurement group_id="O4" value="6.8"/>
                    <measurement group_id="O5" value="8.9"/>
                    <measurement group_id="O6" value="12.5"/>
                    <measurement group_id="O7" value="24.2"/>
                    <measurement group_id="O8" value="18.4"/>
                    <measurement group_id="O9" value="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness-Sev (n=234,244,199,203,184,188,152,86,73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.7"/>
                    <measurement group_id="O8" value="0.0"/>
                    <measurement group_id="O9" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Pre-Specified Systemic Events</title>
        <description>Systemic events (fever [fv] ≥ 37.5 degrees Celsius [C], fever ≥ 38 C but ≤ 39 C, fever &gt;39 C but ≤ 40 C, fever &gt; 40 C, decreased [decr] appetite, irritability, increased [incr] sleep, decreased sleep, hives, use of medication [med] to treat symptoms [sx], and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>During the 4-day period after each dose</time_frame>
        <population>The safety population included all subjects who received at least 1 dose of vaccine, (n) = number of participants reporting yes for at least 1 day or no for all days.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Dose 1</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 2 months of age (infant series).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC Dose 1</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a vaccine containing Pentavac at 2 months of age (infant series).</description>
          </group>
          <group group_id="O3">
            <title>13vPnC Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a vaccine containing Pentavac at 3 months of age (infant series).</description>
          </group>
          <group group_id="O4">
            <title>7vPnC Dose 2</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a vaccine containing Pentavac at 3 months of age (infant series).</description>
          </group>
          <group group_id="O5">
            <title>13vPnC Dose 3</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 4 months of age (infant series).</description>
          </group>
          <group group_id="O6">
            <title>7vPnC Dose 3</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a vaccine containing Pentavac at 4 months of age (infant series).</description>
          </group>
          <group group_id="O7">
            <title>13vPnC/13vPnC Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O8">
            <title>7vPnC/7vPnC Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a vaccine containing Pentavac at 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O9">
            <title>7vPnC/13vPnC Toddler Dose</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Pentavac at 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Systemic Events</title>
          <description>Systemic events (fever [fv] ≥ 37.5 degrees Celsius [C], fever ≥ 38 C but ≤ 39 C, fever &gt;39 C but ≤ 40 C, fever &gt; 40 C, decreased [decr] appetite, irritability, increased [incr] sleep, decreased sleep, hives, use of medication [med] to treat symptoms [sx], and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>The safety population included all subjects who received at least 1 dose of vaccine, (n) = number of participants reporting yes for at least 1 day or no for all days.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="309"/>
                <count group_id="O3" value="302"/>
                <count group_id="O4" value="309"/>
                <count group_id="O5" value="302"/>
                <count group_id="O6" value="309"/>
                <count group_id="O7" value="273"/>
                <count group_id="O8" value="152"/>
                <count group_id="O9" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fv≥38°C,≤39°C(n=244,250,212,217,201,208,174,99,83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5"/>
                    <measurement group_id="O2" value="10.0"/>
                    <measurement group_id="O3" value="19.8"/>
                    <measurement group_id="O4" value="25.3"/>
                    <measurement group_id="O5" value="26.9"/>
                    <measurement group_id="O6" value="27.9"/>
                    <measurement group_id="O7" value="36.8"/>
                    <measurement group_id="O8" value="41.4"/>
                    <measurement group_id="O9" value="42.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fv&gt;39°C,≤40°C(n=238,245,201,205,184,191,153,89,73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.4"/>
                    <measurement group_id="O3" value="1.0"/>
                    <measurement group_id="O4" value="2.4"/>
                    <measurement group_id="O5" value="0.5"/>
                    <measurement group_id="O6" value="1.6"/>
                    <measurement group_id="O7" value="4.6"/>
                    <measurement group_id="O8" value="2.2"/>
                    <measurement group_id="O9" value="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fv &gt;40°C (n=238,245,200,205,184,190,153,88,73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.5"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.7"/>
                    <measurement group_id="O8" value="0.0"/>
                    <measurement group_id="O9" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decr appetite(n=243,251,211,218,194,199,167,96,83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.7"/>
                    <measurement group_id="O2" value="23.1"/>
                    <measurement group_id="O3" value="18.5"/>
                    <measurement group_id="O4" value="26.1"/>
                    <measurement group_id="O5" value="23.2"/>
                    <measurement group_id="O6" value="21.1"/>
                    <measurement group_id="O7" value="29.3"/>
                    <measurement group_id="O8" value="34.4"/>
                    <measurement group_id="O9" value="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (n=261,265,232,238,217,211,178,99,91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.4"/>
                    <measurement group_id="O2" value="52.5"/>
                    <measurement group_id="O3" value="48.3"/>
                    <measurement group_id="O4" value="49.6"/>
                    <measurement group_id="O5" value="41.9"/>
                    <measurement group_id="O6" value="40.3"/>
                    <measurement group_id="O7" value="50.6"/>
                    <measurement group_id="O8" value="46.5"/>
                    <measurement group_id="O9" value="50.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incr sleep (n=256,259,215,227,194,204,163,92,81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.0"/>
                    <measurement group_id="O2" value="41.3"/>
                    <measurement group_id="O3" value="28.4"/>
                    <measurement group_id="O4" value="32.2"/>
                    <measurement group_id="O5" value="23.7"/>
                    <measurement group_id="O6" value="28.4"/>
                    <measurement group_id="O7" value="21.5"/>
                    <measurement group_id="O8" value="23.9"/>
                    <measurement group_id="O9" value="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decr sleep (n=246,253,,215,218,203,196,168,93,81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0"/>
                    <measurement group_id="O2" value="20.6"/>
                    <measurement group_id="O3" value="26.5"/>
                    <measurement group_id="O4" value="27.1"/>
                    <measurement group_id="O5" value="25.1"/>
                    <measurement group_id="O6" value="20.9"/>
                    <measurement group_id="O7" value="26.2"/>
                    <measurement group_id="O8" value="22.6"/>
                    <measurement group_id="O9" value="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Med-treat sx(n=248,259,224,227,202,214,180,100,89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.0"/>
                    <measurement group_id="O2" value="32.8"/>
                    <measurement group_id="O3" value="38.4"/>
                    <measurement group_id="O4" value="44.5"/>
                    <measurement group_id="O5" value="36.1"/>
                    <measurement group_id="O6" value="42.1"/>
                    <measurement group_id="O7" value="47.8"/>
                    <measurement group_id="O8" value="54.0"/>
                    <measurement group_id="O9" value="55.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Med-prevent sx(n=252,260,221,236,201,213,181,99,85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5"/>
                    <measurement group_id="O2" value="34.6"/>
                    <measurement group_id="O3" value="36.7"/>
                    <measurement group_id="O4" value="40.3"/>
                    <measurement group_id="O5" value="28.4"/>
                    <measurement group_id="O6" value="37.6"/>
                    <measurement group_id="O7" value="38.7"/>
                    <measurement group_id="O8" value="44.4"/>
                    <measurement group_id="O9" value="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the 3-Dose Infant Series of 13vPnC</title>
        <description>Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated.</description>
        <time_frame>One month after the 3-Dose Infant Series (at 5 months of age)</time_frame>
        <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (n) = number of participants with a determinate antibody concentration for the specified serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the 3-Dose Infant Series of 13vPnC</title>
          <description>Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated.</description>
          <population>The evaluable immunogenicity (per protocol) population was the primary analysis population consisting of eligible subjects who adhered to the protocol requirements, had valid and determinate assay results, and had no other major protocol violations; (n) = number of participants with a determinate antibody concentration for the specified serotype.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common Serotypes - Serotype 4 (n=244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" lower_limit="1.14" upper_limit="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 6B (n=241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" lower_limit="0.62" upper_limit="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 9V (n=238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" lower_limit="1.03" upper_limit="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 14 (n=236)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.74" lower_limit="2.38" upper_limit="3.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 18C (n=242)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" lower_limit="1.26" upper_limit="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 19F (n=241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.55" lower_limit="1.42" upper_limit="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common Serotypes - Serotype 23F (n=244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" lower_limit="0.80" upper_limit="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 1 (n=240)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" lower_limit="1.07" upper_limit="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 3 (n=242)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" lower_limit="1.13" upper_limit="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 5 (n=243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" lower_limit="0.82" upper_limit="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 6A (n=243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" lower_limit="0.82" upper_limit="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 7F (n=238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" lower_limit="1.73" upper_limit="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Serotypes - Serotype 19A (n=244)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.10" lower_limit="1.87" upper_limit="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>13vPnC Infant Series</title>
          <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series). Adverse events were collected from dose 1 to approximately one month after dose 3.</description>
        </group>
        <group group_id="E2">
          <title>7vPnC Infant Series</title>
          <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series). Adverse events were collected from dose 1 to approximately one month after dose 3.</description>
        </group>
        <group group_id="E3">
          <title>13vPnC Post-Infant Series</title>
          <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series). Adverse events were collected from approximately one month after dose 3 to toddler dose.</description>
        </group>
        <group group_id="E4">
          <title>7vPnC Post-Infant Series</title>
          <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a vaccine containing Pentavac at 2, 3, and 4 months of age (infant series). Adverse events were collected from approximately one month after dose 3 to toddler dose.</description>
        </group>
        <group group_id="E5">
          <title>13vPnC/13vPnC Toddler Dose</title>
          <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with a vaccine containing Pentavac at 12 months of age (toddler dose). Adverse events were collected for approximately one month after toddler dose.</description>
        </group>
        <group group_id="E6">
          <title>7vPnC/7vPnC Toddler Dose</title>
          <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a vaccine containing Pentavac at 12 months of age (toddler dose). Adverse events were collected for approximately one month after toddler dose.</description>
        </group>
        <group group_id="E7">
          <title>7vPnC/ 13vPnC Toddler Dose</title>
          <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with a vaccine containing Pentavac at 12 months of age (toddler dose). Adverse events were collected for approximately one month after toddler dose.</description>
        </group>
        <group group_id="E8">
          <title>13vPnC / 13vPnC 6-Month Follow-up</title>
          <description>Participants received one single 0.5 mL dose of 13vPnC coadministered with Pentavac at 2, 3, and 4 months of age (infant series) and 12 months of age (toddler). Adverse events were collected for approximately six months after last visit.</description>
        </group>
        <group group_id="E9">
          <title>7vPnC / 7vPnC 6-Month Follow-up</title>
          <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Pentavac at 2, 3, and 4 months of age (infant series) and 12 months of age (toddler). Adverse events were collected for approximately six months after last visit.</description>
        </group>
        <group group_id="E10">
          <title>7vPnC / 13vPnC 6-Month Follow-up</title>
          <description>Participants received one single 0.5 mL dose of 7vPnC coadministered with Pentavac at 2, 3, and 4 months of age (infant series) and at 12 months of age (toddler). Adverse events were collected for approximately six months after last visit.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Foreign body aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Local Reactions</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="142" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="162" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="125" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="64" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="63" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Dacryostenosis congenital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Hypermetropia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Regurgitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Dental discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Infantile colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥38°C but ≤39°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Fever ≥38 degrees C but ≤39 degrees C</description>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="250"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="64" subjects_at_risk="174"/>
                <counts group_id="E6" subjects_affected="41" subjects_at_risk="99"/>
                <counts group_id="E7" subjects_affected="35" subjects_at_risk="83"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥38°C but ≤39°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Fever ≥38 degrees C but ≤39 degrees C</description>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥38°C but ≤39°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Fever ≥38 degrees C but ≤39 degrees C</description>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="208"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;39°C but ≤40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Fever &gt;39 degrees C but ≤40 degrees C</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;39°C but ≤40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Fever &gt;39 degrees C but ≤40 degrees C</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;39°C but ≤40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Fever &gt;39 degrees C but ≤40 degrees C</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Fever &gt;40 degrees C</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Fever &gt;40 degrees C</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt;40°C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Fever &gt;40 degrees C</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Decreased appetite</description>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="49" subjects_at_risk="167"/>
                <counts group_id="E6" subjects_affected="33" subjects_at_risk="96"/>
                <counts group_id="E7" subjects_affected="26" subjects_at_risk="83"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Decreased appetite</description>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Decreased appetite</description>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="199"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Irritability</description>
                <counts group_id="E1" subjects_affected="142" subjects_at_risk="261"/>
                <counts group_id="E2" subjects_affected="139" subjects_at_risk="265"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="90" subjects_at_risk="178"/>
                <counts group_id="E6" subjects_affected="46" subjects_at_risk="99"/>
                <counts group_id="E7" subjects_affected="46" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Irritability</description>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Irritability</description>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="211"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Increased sleep</description>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="259"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="35" subjects_at_risk="163"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="92"/>
                <counts group_id="E7" subjects_affected="19" subjects_at_risk="81"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Increased sleep</description>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="227"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Increased sleep</description>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="204"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Decreased sleep</description>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="246"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="253"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="44" subjects_at_risk="168"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="93"/>
                <counts group_id="E7" subjects_affected="25" subjects_at_risk="81"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Decreased sleep</description>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="215"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Decreased sleep</description>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Milk allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Rhinotracheitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Roseola</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Rhinolaryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Viral skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Dacryocystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Erythema infectiosum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Genital candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Human herpesvirus 6 infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Bacteria stool identified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Facial palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Allergic respiratory disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Heat rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Nail bed inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Rash morbilliform</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Eczema asteatotic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Tenderness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Tenderness (any)=present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="95" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="43" subjects_at_risk="96"/>
                <counts group_id="E7" subjects_affected="57" subjects_at_risk="89"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tenderness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Tenderness (any)</description>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="225"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tenderness (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Tenderness (any)</description>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tenderness (Significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Tenderness (significant)=present and interfered with limb movement.</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="155"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tenderness (Significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Tenderness (significant)</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="208"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tenderness (Significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Tenderness (significant)</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="188"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Induration (any)=present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="99" subjects_at_risk="185"/>
                <counts group_id="E6" subjects_affected="57" subjects_at_risk="99"/>
                <counts group_id="E7" subjects_affected="58" subjects_at_risk="97"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (any)</description>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="235"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (any)</description>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="217"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="219"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Induration (mild)=0.5 centimeters (cm) to 2.0 cm.</description>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="87" subjects_at_risk="181"/>
                <counts group_id="E6" subjects_affected="55" subjects_at_risk="99"/>
                <counts group_id="E7" subjects_affected="55" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (mild)</description>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="232"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Induration (mild)</description>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Induration (moderate)=2.5 cm to 7.0 cm.</description>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="246"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="159"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="88"/>
                <counts group_id="E7" subjects_affected="17" subjects_at_risk="82"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (moderate)</description>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="208"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Induration (moderate)</description>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="194"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Induration (severe) &gt;7.0 cm.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Induration (severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Induration (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Induration (severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Erythema (any)=present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="260"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="125" subjects_at_risk="187"/>
                <counts group_id="E6" subjects_affected="64" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="63" subjects_at_risk="99"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Erythema (any)</description>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="140" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Erythema (any)</description>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="132" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Erythema (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Erythema (mild)=0.5 cm to 2.0 cm.</description>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="259"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="108" subjects_at_risk="180"/>
                <counts group_id="E6" subjects_affected="58" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="57" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Erythema (mild)</description>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="136" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Erythema (mild)</description>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="123" subjects_at_risk="221"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Erythema (moderate)=2.5 cm to 7.0 cm.</description>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="40" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="79"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Erythema (moderate)</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="205"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="206"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Erythema (moderate)</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Erythema (severe) &gt;7.0 cm.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Erythema (severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (Severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Erythema (severe)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Child abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>U. S. Contact Center</name_or_title>
      <organization>Wyeth</organization>
      <email>clintrialresults@wyeth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

